Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29856185 | 0.85 | DYRK1A (0.51) | DYRK1AGSK3BKCNH2KDM4CNTRK1 | |
| SCHEMBL29856145 | 0.74 | POLB (0.51) | DYRK1AGSK3BCNR2CNR1NTRK1 | |
| SCHEMBL4859713 | 0.73 | DYRK1A (0.67) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL31165814 | 0.73 | DYRK1A (0.67) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL21351692 | 0.73 | DYRK1A (0.51) | DYRK1AGSK3BKCNH2KDM4CNTRK1 | |
| SCHEMBL25421887 | 0.72 | DYRK1A (0.63) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL25646426 | 0.71 | DYRK1A (1.00) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL4858853 | 0.66 | DYRK1A (0.57) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL25421891 | 0.66 | DYRK1A (0.57) | DYRK1AGSK3BKCNH2KDM4C | |
| SCHEMBL29856274 | 0.65 | ROCK2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022169974-A1 | INHIBITORS OF URAT1 AND PHARMACEUTICAL USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |